SUCCINYLCHOLINE LABELING CARDIAC ARREST RISK STATEMENT SHOULD BE WARNING, NOT A CONTRAINDICATION, FDA COMMITTEE SAYS; AT-RISK POPULATION NARROWED
Executive Summary
Succinylcholine neuromuscular blocking agent product labeling should contain a box warning of the possibility of hyperkalemia- induced cardiac arrest in male pediatric patients, FDA's Anesthetic & Life Support Drugs Advisory Committee recommended unanimously in three votes June 9.